About 30 Million Tests a Week May Be Needed to Reopen Communities(1)
This Possible $157 Billion “Testing Economy” Could Give Medivolve (NEO:MEDV)(OTC:COPRF) a Big Shot in the Arm(1)
Like me, you’re exhausted from hearing about the health scare.
We’re exhausted from the lockdowns, from social distancing, from having to wear masks.
Many of us are burning out from it, claim psychologists. Many people seem to be feeling worn out and unable to mentally cope with the issue. Others believe the health scare will be around longer than expected. There appear to be dashed hopes of easing restrictions and increased fatigue.
But there’s good news. Eventually, we will undoubtedly get back to some sort of normal. But, to get to that point, we need more testing.
Over the last several months, the stock appears to have broken from multi-month consolidation at around 14 cents a share to approximately 70 cents. After a brief pullback to about 40 cents, the stock seems to have caught double bottom support. With what looks to be far more testing required thanks to the health situation, Medivolve has the potential to see more momentum.
Plus, several of its technical indicators look positive, as well, including its 20 – 50 Day MACD Oscillator, 20 – 100 Day MACD Oscillator, 20 – 200 Day MACD Oscillator, 50 – 100 Day MACD Oscillator, 50 – 150 Day MACD Oscillator, 50 – 200 Day MACD Oscillator, 100 Day Moving Average, 150 Day Moving Average, 200 Day Moving Average, and 100 – 200 Day MACD Oscillator.(7)
Medivolve is a publicly-traded company that seeks out disruptive technologies, groundbreaking innovations, and exclusive partnerships to help combat the current health issue.
With a seasoned executive team and renowned global advisors that provide expertise across industries, Medivolve appears to offer shareholders diversified and cutting-edge exposure to the medical space across geographic regions and three focus areas: detection, prevention, and treatment.
It’s recently identified the “testing economy” as the most potentially lucrative.
Medivolve seems to believe that the “testing economy” could have lucrative potential. This appears to echo Wells Fargo’s claim that this medical subsector could be worth about $157 billion by 2022.(1)
With that being the case, the company’s subsidiary, Collection Sites, seems to have been rolling out hundreds of testing sites across the United States. It appears to be partnering with major real estate owners such as Simon Property Group, Sandor, H&S Energy Products, and others to accomplish this.(1)
Better, Collection Sites reportedly provides quick and convenient testing in conjunction with a CLIA registered lab, including rapid antigen, PCR, and rapid antibody tests with insurance options.
All to help millions get tested.
Furthermore, its average price per test at approximately $96 appears to be significantly more cost-effective than the median price for testing of about $127. About one in five tests also seems to cost more than about $200.(1)
In an effort to flatten the curve, the company:(1)
- Has mobile site for 10 minute RT-PCR, antigen and antibody testing
- Same day results from certified high complexity Alcala Labs – around 98% accuracy on select tests
- Approximately 740+ locations throughout the United States
- Can provide up to roughly 150 tests per cube per day at an average price just under $100
- Has a scalable business model with low cost of customer acquisition
Medivolve (NEO:MEDV)(OTC:COPRF) Acquired 100% of Noble Bioscience Corp and its Surface Shield Technology(6)
The company seems to have entered into an agreement to acquire 100% of Noble Bioscience Corp., which claims to hold the agency rights to Nuturell’s Surface Shield technology in the United States, Canada, and the Caribbean. Medivolve’s subsidiary Collection Sites, LLC will seemingly lead the United States sales effort on behalf of the company.(6)
Nuturell’s Surface Shield technology was created to overcome the limitations of standard harsh chemical disinfectants and cleaning agents that suffer from various constraints such as their harmfulness, corrosive nature, and bacterial resistance. Nuturell’s surface shield claims that it can kill a broad range of pathogens in only about 30 seconds of contact and is considered a “green” surface shield. Silver has been well-known as an antimicrobial agent and for its medicinal importance due to the remarkable pathogen-killing properties.
Douglas Sommerville — CEO
Doug has held prominent roles at pharmaceutical giants such as Teva Pharmaceuticals and Baxter Healthcare International. In this role as Head of Teva Canada, Mr. Sommerville was responsible for Teva’s third-largest global subsidiary, with sales of over roughly $1.3 billion. Doug was also the Chairman of the Canadian Generic Pharmaceutical Association until he retired from Teva Canada in 2018. He holds an MBA from the Schulich School of Business.
Deborah Battiston – CFO
Deborah Battiston is a CPACGA, she obtained her BA in Economics from the University of Guelph and holds an ICD.D from the University of Toronto’s Rotman School of Management. Deborah has an extensive background with over 25 years of financial management, including public companies, mergers and acquisitions, tax, and financing.
Aaron Atin – Corporate Secretary
Aaron Atin is a corporate and securities lawyer with extensive experience in securities, M&A, and corporate finance. He holds an engineering diploma from Centennial College, a Bachelor of Arts from the University of Waterloo, and a J.D. from the University of Toronto, Faculty of Law.
Dr. Beverley Richardson — Director
Dr. Beverley J. Richardson is a renowned psychotherapeutic practitioner whose collaborative efforts and clinical influence are reflected in some of the most compelling and effective addiction and behavioral health programs in North America, which include: Sierra Tucson (Arizona), the Meadows (Arizona), and Betty Ford Centre (California). She has a Doctorate Degree in Psychology and is a B.C. Registered Clinical Counsellor, Internationally Certified Eating Disorder Specialist, and EMDR Level II Trauma Therapist. Dr. Richardson has integrated her extensive health and wellness experience with her entrepreneurial spirit to form her nutraceutical and bioscience research and development enterprises.
Daniyal Baizak – Director
Daniyal is a seasoned professional with considerable experience providing financial and strategic advice on mergers, acquisitions, and managing multiple projects for various private and public companies. With expertise in Central Asian and Russian markets, Daniyal plays a crucial role in navigating and finding new investment opportunities in frontier and emerging markets for F&M.
Wen Ye – Executive Chairman
Ms. Ye is a CPA, CGA, and holds a Bachelor of Commerce degree from Laurentian University. Ms. Ye brings over 17 years of corporate and finance management experience in the public mining, securities, and logistics sectors.
Members of Medivolve’s Medical Advisory Board represent a unique brain trust. Comprised of thought leaders, influencers, opinion makers, and leaders within their respective fields, areas of expertise, sector, and industry – they are committed to Medivolve’s mission to bring medical breakthroughs to market with power, grace, and ease.
Members of the Medical Advisory Board will help fulfill Medivolve’s mission of searching for and investing in breakthrough sciences, technologies, research, or resolutions to empower the betterment of mankind.
Dr. GLENN COPELAND — ADVISOR
Possessing over 45 years of experience in orthopedic treatment and sports medicine, Dr. Glenn Copeland is one of North America’s most prominent foot and ankle specialists. Between 2002 and 2008, Dr. Copeland was selected to be the founder, Chairman, and CEO of Cleveland Clinic Canada. Cleveland Clinic is universally regarded as one of the top three medical institutions in the world.
Dr. JOSEPH SUGERMAN — ADVISOR
Dr. Sugerman is a board-certified otolaryngologist who manages a private practice in Los Angeles focused on managing voice disorders. He is a past Clinical Chief at Cedars-Sinai Medical Centre. He is also a former board member of MGM Mirage. Dr. Sugerman was a Clinical Instructor at the University of Southern California (USC) Keck School of Medicine and the University of California at Los Angeles (UCLA) Department of Otolaryngology: Head and Neck Surgery Division.
Dr. LAWRENCE STEINMAN — ADVISOR
Dr. Steinman is a Professor of Neurology, Neurological Sciences, and Paediatrics at Stanford University and was Chair of the Stanford Program in Immunology from 2001 to 2011. His research focuses on antigen-specific tolerance in autoimmune disease and in gene therapy for degenerative neurologic disorders. Dr. Steinman has elucidated what provokes relapses and remissions in multiple sclerosis (MS). He serves as an attending neurologist at Stanford’s Lucille Packard Children’s Hospital.
Mike is widely recognized across Canada as a health care champion and advocate. As a principal with Grosso McCarthy, Mike has over 15 years of experience with the Ontario Ministry of Health and Long Term Care and over 25 years in health policy and delivery. In 2001, he was appointed Senior Policy Advisor to the Ontario Minister of Health. Mike has also been on the front lines of health care, working for 18 years as a psychiatric nurse.
Mr. Rogers co-founded the Quantum Fund, a global- investment partnership. After retiring – at age 37, Mr. Rogers continued to manage his own portfolio and serve as a finance professor at the Columbia University Graduate School of Business. Mr. Rogers also presciently saw the formation of the subprime mortgage crisis a year before it erupted.
Mike has served as the Chief Performance Advisor to LeBron James for over 14 years and counting. His experience includes working with NBA, NFL, MLB, PGA, and top NCAA athletes. Mike attended the University of Texas- Pan American and graduated with a degree in Health Education. Mike is licensed and nationally certified by the Accredited National athletic Trainers Association and is a 14-year member of The National Basketball Athletic Trainers Association.
Richard is an advocate and researcher on the subject of human betterment through effective and responsible investment. An internationally best-selling author and highly sought-after speaker, Richard has shared the stage with many former presidents.
Source 2: https://chicago.suntimes.com/well/2021/1/29/22227020/emotional-exhaustion-cope-coping-depression-covid-pandemic-coronavirus-mental-health-wellness
Source 3: https://medivolve.ca/collection-sites-expands-convenient-covid-19-testing-across-america-with-25-additional-testing-sites/
Source 4: https://www.barchart.com/stocks/quotes/MEDV.NE/interactive-chart
Source 5: https://medivolve.ca/collection-sites-expands-convenient-covid-19-testing-across-america-with-25-additional-testing-sites/
Source 6: https://medivolve.ca/medivolve-enters-into-agreement-to-acquire-100-of-noble-bioscience-corp-and-its-agency-rights-to-nuturells-covid-19-surface-shield-technology/
Source 7: https://www.barchart.com/stocks/quotes/MEDV.NE/opinion
This website / media webpage is owned, operated and edited by TD Media LLC. Any wording found on this website / media webpage or disclaimer referencing to “I” or “we” or “our” or “TD Media” refers to TD Media LLC. This website / media webpage is a paid advertisement, not a recommendation nor an offer to buy or sell securities. Our business model is to be financially compensated to market and promote small public companies. By reading our website / media webpage you agree to the terms of our disclaimer, which are subject to change at any time. We are not registered or licensed in any jurisdiction whatsoever to provide investing advice or anything of an advisory or consultancy nature and are therefore are unqualified to give investment recommendations. Always do your own research and consult with a licensed investment professional before investing. This communication is never to be used as the basis for making investment decisions and is for entertainment purposes only. At most, this communication should serve only as a starting point to do your own research and consult with a licensed professional regarding the companies profiled and discussed. Conduct your own research. Companies with low price per share are speculative and carry a high degree of risk, so only invest what you can afford to lose. By using our service you agree not to hold our site, its editor’s, owners, or staff liable for any damages, financial or otherwise, that may occur due to any action you may take based on the information contained within our website / media webpage.We do not advise any reader take any specific action. Losses can be larger than expected if the company experiences any problems with liquidity or wide spreads. Our website / media webpage are for entertainment purposes only. Never invest purely based on our alerts. Gains mentioned in our website / media webpage may be based on end-of-day or intraday data. This publication and their owners and affiliates may hold positions in the securities mentioned in our alerts, which we may sell at any time without notice to our subscribers, which may have a negative impact on share prices. If we own any shares we will list the information relevant to the stock and number of shares here. TD Media business model is to receive financial compensation to promote public companies. To conduct investor relations advertising, marketing and publicly disseminate information not limited to our Websites, Email, SMS, Push Notifications, Influencers, Social Media Postings, Ticker Tags, Press Releases, Online Interviews, Podcasts, Videos, Audio Ads, Banner Ads, Native Ads, Responsive Ads. This compensation is a major conflict of interest in our ability to be unbiased regarding. Therefore, this communication should be viewed as a commercial advertisement only. We have not investigated the background of the hiring third party or parties. The third party, profiled company, or their affiliates likely wish to liquidate shares of the profiled company at or near the time you receive this communication, which has the potential to hurt share prices. Any non-compensated alerts are purely for the purpose of expanding our database for the benefit of our future financially compensated investor relations efforts. Frequently companies profiled in our alerts may experience a large increase in volume and share price during the course of investor relations marketing, which may end as soon as the investor relations marketing ceases. Our emails may contain forward-looking statements, which are not guaranteed to materialize due to a variety of factors
We do not guarantee the timeliness, accuracy, or completeness of the information on our website / media webpage. The information in our website / media webpage is believed to be accurate and correct, but has not been independently verified and is not guaranteed to be correct. The information is collected from public sources, such as the profiled company’s website and press releases, but is not researched or verified in any way whatsoever to ensure the publicly available information is correct. Furthermore, TD Media often employs independent contractor writers who may make errors when researching information and preparing these communications regarding profiled companies. Independent writers’ works are double-checked and verified before publication, but it is certainly possible for errors or omissions to take place during editing of independent contractor writer’s communications regarding the profiled company(s). You should assume all information in all of our communications is incorrect until you personally verify the information, and again are encouraged to never invest based on the information contained in our written communications. The information in our disclaimers is subject to change at any time without notice.
Pursuant to an agreement between TD Media LLC and Winning Media LLC, TD Media LLC has been hired for a period beginning on 03/08/2021 and ending on 05/07/2021 to publicly disseminate information about (COPRF:US) (MEDV:CA) via digital communications. We have been paid two hundred fifty thousand dollars USD. We own zero shares of (COPRF:US) (MEDV:CA)
(Last updated: 02-21-2024 2:15:05)
Address: 65 Queen Street West Suite 800 Toronto ON M5H 2M5 CA
Phone: +1 416 861-5888
Medivolve Inc is an investment management company that offers a diversified investment option in the COVID-19 medical space across three areas; prevention, detection, and treatment. The focus of the company is to sell COVID-19 IgG/IgM antibody tests.